Interpace Biosciences announced preliminary, unaudited revenue for Q3 2026 is expected between $10.1 million and $10.4 million. This represents a quarter-over-quarter growth of approximately 11% to 14% compared to Q2 2026, and a year-over-year increase of about 15% to 18% compared to Q3 2025. The company specializes in molecular diagnostic tests for personalized medicine, including thyroid tests. Final financial results will be reported later after audit and closing procedures.
Interpace Biosciences announced preliminary Q3 2026 revenue expected between $10.1 million and $10.4 million, marking a quarter-over-quarter growth of approximately 11% to 14%. For readers following the health sector, here is Pluang's market snapshot as of Oct 15, 2026 05:21 WIB: out of 150 priced health-sector US stocks, 92 rose and 58 fell. Notable movers include ALMS at USD 6.08 with a 1-day change of -7.39%, HALO at USD 117.45 up 7.14%, and HIMS at USD 27.65 down 6.93%.
Coastal Community Bank has committed $5 million to the Solomon Hess SBA Loan Fund to support small businesses in Snohomish and King Counties. This investment helps expand access to capital for businesses that may not qualify for traditional loans, fo...
Stephany Insurance LLC, a fourth-generation independent agency in Wexford, PA, is highlighted in a new 2026 guide for helping small businesses in Pittsburgh's North Hills identify and close insurance coverage gaps caused by rising premiums. The guide...
The Knowles-Rowland House, a $13.96 million redevelopment project by Bread of Life Inc., has opened in Midtown Houston, providing 31 permanent supportive housing units for individuals exiting chronic homelessness. The building, formerly a fire-damage...
ATLAS SP Partners, majority owned by Apollo funds, announced the pricing of $750 million senior notes due 2032 with a fixed 6.25% interest rate until November 2031, then switching to a floating rate based on SOFR plus a spread. The notes, issued by A...
Bending Spoons led market gainers with a 41.2% rise after Berkshire Hathaway increased its stake to 4% by investing an additional $330 million. Antelope Enterprise gained 36.4%, and NEXGEL rose 32.1% following a reverse stock split. Liquidia advanced...
